We’re dedicated to the research and development of therapies for people suffering from debilitating diseases that rob them of key muscle functions.
We’re advancing muscle biology-driven treatments for diseases characterized by compromised muscle function, muscle weakness, and fatigue.
We have conducted more than 50 clinical trials as we strive to bring important new medicines to patients with diseases like ALS, heart failure, and SMA.
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators.
Cytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance.
Co-Founder, Cytokinetics; Professor, Stanford School of Medicine
Department of Biochemistry